



Oceanana
T h e r a p e u t i c s , I n c .



Redefining Specialty Therapeutics

Corporate Presentation
June 2011

Oceana Therapeutics Profile



Proven Value Creation Team

- Founded mid-2008 by the team that pioneered the *Buy & Build, Search & Develop* pharmaceutical business model
 - Identify/acquire/maximize the potential of approved & late-stage specialty drugs

Unique Specialty Therapeutics Model of Selective Acquisitions

- Broaden model to include specialty medical devices, pharmaceuticals & diagnostics
- Expand scope of strategy to take advantage of global opportunities

Organized for Performance and Delivery


- Focus on GI and Urology niche specialties: concentrated, addressable markets
- Completed 1st acquisition & initiated global commercial operations in mid-2009
- Strong commercial structure with 40+ team (> 20 in sales/marketing)
- Expanding portfolio of approved and late-stage products
 - Deflux[®] (in-market); Solesta[®] (FDA panel recommends approval)
- Strong financial support: Kelso & Co. and Frazier Healthcare Ventures


Global Positioning



Worldwide Headquarters.
Edison, New Jersey

EU Headquarters.
Dublin, Ireland





In the Management of Children
With Grade II-IV Vesicoureteral Reflux (VUR):
**Stop Febrile UTIs
in Their Tracts**

Deflux

Deflux[®]


Vesicoureteral Reflux (VUR)




Deflux[®]

- **Flow of urine from the bladder backs into the kidneys**
- **Incidence: 1% - 3% of children in the US**
 - Children under age of one with a UTI have a 70% incidence of VUR
- **Complications of VUR**
 - Hydroureter (swelling in the ureter)
 - Hydronephrosis (swelling in the kidney)
 - Infection in the urinary tract
 - Kidney disease / failure

Normal flow of urine (blue arrows)



Urine flowing the wrong way (red arrows) VUR



Why Deflux[®] for VUR



- **The only FDA approved treatment for pediatric VUR (Grades II – IV)**
 - Also approved for VUR, stress incontinence and other urologic indications in Europe, Canada and other regions
- **Excellent Efficacy**
 - ~4x better reduction in febrile UTI (FUTI) rates than antibiotic treatment
 - Incidence of FUTIs post Deflux was comparable to major surgery
 - >6-fold post-treatment reduction in incidence of FUTIs per year
- **Excellent Safety Profile**
 - > 50,000 children treated with no reported persistent adverse events
- **Excellent Durability**
 - Provides platform for permanent tissue formation
- **Excellent Patient/Physician Incentives**
 - Simple, minimally invasive, ~20 minute outpatient procedure
 - Attractive reimbursement profile for physicians



Introducing the new
non-surgical option
for fecal incontinence



Fecal (Bowel) Incontinence – FI



- **FI is the loss of regular bowel control**
- **Affects large patient population**
 - 33% of elderly people in nursing homes or hospitals
 - 23% of stroke patients
 - 7% of healthy patients 65 years and older
 - 2% of all women that delivered one or more children
- **About 50% of patients fail conservative therapy**
- **Complications of FI**
 - Significant decrease in patient Quality of Life (depression, embarrassment)
 - Anal irritation
 - Rectal pain

Why Solesta[®] for FI?




- **FDA's Gastroenterology and Urology Devices Panel met December 2010 and recommended approval; FDA issues Approval Letter May 2011**
 - Anticipate US launch in H2 2011
- **Excellent Efficacy**
 - Exceeded FDA mandated primary clinical endpoints at 6 and 12 months
- **Excellent Safety Profile**
 - 206 patient study (US / EU) for with no notable adverse events reported
- **Excellent Physician/Patient Incentives**
 - Satisfies unmet medical need between conservative management and surgery
 - Minimally invasive office-based procedure that's a durable treatment option
 - Improves patients' quality of life

Solesta® for FI - How does it work?



 Solesta®

- **Four sub-mucosal injections are administered above the dentate line (anal canal) and internal sphincter**
- **Once injected, Solesta fills in and narrows the anal canal**
- **Procedure results in significant reduction of fecal incontinence episodes**



Growth Drivers



- **Leverage existing sales/marketing infrastructure**
 - Increase penetration of Deflux in key global markets
 - Anticipated 2011 US launch of Solesta
 - Build awareness of products to drive growth in existing markets and expand into newly approved markets
 - Manage and increase sales force as needed to fuel growth
- **Active pursuit of acquisition strategy**
 - Specialty medical devices, pharmaceuticals and diagnostics, for both approved and late-stage products
 - Focused on core therapeutic niche areas
 - New deal prospects currently in active discussions

Conclusion



Creating significant revenue/valuation growth

- ① **A Specialty Therapeutics business model**
- ② **Strong management & niche therapeutic focus**
- ③ **Existing product revenues**
- ④ **Near term U.S. opportunity for Solesta**
- ⑤ **Well positioned for global growth opportunities**
- ⑥ **Leverageable sales/marketing infrastructure**
- ⑦ **Deep financial backing**